Nature Reviews Drug Discovery

Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications

Teemu Haikarainen, Anniina T. Virtanen, Benjamin F. Cravatt et al. Apr 01, 2026 pp. 268-289 10.1038/s41573-025-01336-9

Trends in target novelty in oncology R&D

Jack Cuthbertson, Sakis Paliouras, Tatiana Kolesnikova Apr 01, 2026 pp. 262-263 10.1038/d41573-025-00199-4

Can a first disease-modifying osteoarthritis drug make it past the FDA?

Ken Garber Apr 01, 2026 pp. 251-253 10.1038/d41573-026-00047-z

Upcoming FDA approval decisions in Q2 2026

Kaniaw Dilzer Apr 01, 2026 pp. 259-259 10.1038/d41573-026-00046-0

Single-dose sleeping sickness drug set for approval

Asher Mullard Apr 01, 2026 pp. 255-255 10.1038/d41573-026-00044-2

Reshaping Pfizer’s drug discovery priorities

Asher Mullard Apr 01, 2026 pp. 260-261 10.1038/d41573-026-00045-1

In vivo CAR-T cells target fibrogenic cells in MASH

M. Teresa Villanueva Apr 01, 2026 pp. 266-266 10.1038/d41573-026-00043-3

Synthetic lethal strategy targets p53-deficient cancers

Alex Eccleston Apr 01, 2026 pp. 265-265 10.1038/d41573-026-00042-4

FDA approves dwarfism drug

Asher Mullard Apr 01, 2026 pp. 254-254 10.1038/d41573-026-00040-6

Top companies and drugs by sales in 2025

Paul Verdin Apr 01, 2026 pp. 258-258 10.1038/d41573-026-00041-5

Digital endpoints in clinical trials: building the business case for systematic adoption

Jennifer C. Goldsack, Sarah Ernst, Marissa F. Dockendorf et al. Apr 01, 2026 pp. 256-257 10.1038/d41573-026-00033-5

An allosteric site on cereblon

Sarah Crunkhorn Apr 01, 2026 pp. 267-267 10.1038/d41573-026-00039-z

Targeting vascular smooth muscle cells

Sarah Crunkhorn Apr 01, 2026 pp. 267-267 10.1038/d41573-026-00036-2

Promoting remyelination

Sarah Crunkhorn Apr 01, 2026 pp. 267-267 10.1038/d41573-026-00038-0

Inhibiting advillin in glioblastoma

Sarah Crunkhorn Apr 01, 2026 pp. 267-267 10.1038/d41573-026-00037-1

Author Correction: Novel drug treatments for schizophrenia

Joseph T. Coyle, Steven M. Paul Apr 01, 2026 pp. 331-331 10.1038/s41573-026-01409-3

Gilead pays US$7.8 billion for Arcellx’s next-generation CAR T candidate

Asher Mullard Apr 01, 2026 pp. 254-254 10.1038/d41573-026-00034-4

Clearing cholesterol combats secondary lymphoedema

Sarah Crunkhorn Apr 01, 2026 pp. 264-264 10.1038/d41573-026-00032-6

Accelerating the drug regulatory process through a federated cloud ecosystem

Andrew S. Robertson, Nahid Latif, Raymond C. Votzmeyer et al. Apr 01, 2026 pp. 249-250 10.1038/d41573-026-00014-8

Roads and detours for CAR T cell therapy in autoimmune diseases

Jérôme Avouac, Adi Barzel, Delma Caiati et al. Apr 01, 2026 pp. 290-309 10.1038/s41573-025-01349-4

Novel drug treatments for schizophrenia

Joseph T. Coyle, Steven M. Paul Apr 01, 2026 pp. 310-330 10.1038/s41573-025-01335-w